Patent · US Expired

Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration

US6982256B2 · kind B2 · utility

11Cited by

4References

16Claims

0Family size

Assignee

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG · DE

Inventors

Christine Votteler · Biberach an der Riß, DE
Bernd Kruss · Biberach an der Riß, DE

Key dates

Filing date	Sep 9, 2002
Grant date	Jan 3, 2006
Priority date	—
Expiry date	Sep 9, 2022

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K47/40
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to new formulations for improving the local tolerance of intravenously administered 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine or one of the pharmacologically acceptable acid addition salts thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.